Study protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial

N. de Boer, S. Guloksuz, C. van Baal, L. Willebrands, J. Deenik, C.H. Vinkers, I. Winter-van Rossum, J. Zinkstok, I. Wilting, J.B. Zantvoord, F. Backx, W.E. Swildens, M. Schouw, J. Bogers, F. Hulshof, R. de Knijff, P. Duindam, M. Veereschild, M. Bak, G. FrederixL. de Haan, J. van Os, W. Cahn, J.J. Luykx

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number4
Number of pages11
JournalBMC Psychiatry
Volume21
Issue number1
DOIs
Publication statusPublished - 5 Jan 2021

Keywords

  • Antipsychotic-induced weight gain (AiWG)
  • Lifestyle
  • Metformin
  • Schizophrenia
  • antipsychotic-induced weight gain (aiwg)
  • lifestyle
  • metformin
  • schizophrenia
  • CLOZAPINE
  • METABOLIC SYNDROME
  • RISK
  • SCHIZOPHRENIA
  • INDIVIDUALS
  • INSTRUMENT
  • PHYSICAL-ACTIVITY
  • QUESTIONNAIRE
  • SEVERE MENTAL-ILLNESS
  • INTERVENTION

Cite this